“The TALAPRO-2 results showed that TALZENNA plus XTANDI is the first and only PARP inhibitor in combination with an ARPI to significantly improve survival in patients with metastatic ...

Pfizer may be the last major oncology player to put a wager on a PARP inhibitor in prostate cancer, but the New York pharma appears to have a winning regimen, partly thanks to its Astellas-partnered ...

TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...

TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic ...

(RTTNews) - Pfizer (PFE) Thursday reported positive results from the Phase 3 TALAPRO-2 study of Talzenna, an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide) ...

The PARP inhibitor class is welcoming its second FDA approval in prostate cancer in the span of several weeks. The new approval, for Pfizer, is broader than the first but still limited. The FDA has ...

TALZENNA is approved in over 70 countries, including the U.S., as a once-daily monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer ...

Talzenna (talazoparib) is a brand-name drug that’s prescribed for certain types of breast and prostate cancers in adults. It comes as an oral capsule that’s typically taken once per day. The dosage ...

Adding Talzenna (talazoparib) to Xtandi (enzalutamide) improved the length of time men with metastatic castration-resistant prostate cancer lived before their disease worsened, compared to those who ...

First and only PARP inhibitor plus ARPI combination to demonstrate statistically significant overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer (mCRPC) ...

In mCRPC patients, Talzenna + Xtandi cut death risk by 20%, extending median OS to 45.8 months vs. 37.0 months with Xtandi alone. In HRR-mutated mCRPC, Talzenna + Xtandi reduced death risk by 38%, ...